Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 67Cu-labelled MeCOSar-Tyr3-octreotate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Clarity Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Clarity and Cardinal Health Enter into Agreement for Targeted Copper Theranostics
Details : Cardinal Health will provide cGMP product manufacturing of ready-to-use TCT for Clarity’s U.S.-based clinical trials from its Center for Theranostics Advancement. TCT are radiopharmaceuticals that pair copper-64 (64Cu) and copper-67 (67Cu) for diagnosi...
Brand Name : 67Cu-SARTATE
Molecule Type : Peptide
Upfront Cash : Undisclosed
December 02, 2021
Lead Product(s) : 67Cu-labelled MeCOSar-Tyr3-octreotate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Clarity Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Cardinal Health will provide comprehensive end-to-end 3PL to Sesen Bio in support of commercialization in the U.S. The Company’s lead program, Vicineum is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, ...
Brand Name : VB4-845
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 19, 2020
LOOKING FOR A SUPPLIER?
Reset All
